CAJ | 학술논문

目的通过检测心肌组织中细胞因子表达量的变化来评价卡维地洛对大鼠实验性自身免疫性心肌炎(EAM)的治疗效果及其作用机制。方法大鼠接种肌球蛋白后被分为两组，治疗组每日给予卡维地洛，对照组给予赋形剂，治疗效果在第21天进行评价。结果实验组心肌炎症面积23.07％±1.6％与对照组33.65％±2.71％相比明显减少(P ＜0.0001)，左室短轴缩短率43.52％±3.53％与对照组32.3％±3.31％相比明显提高(P =0.0021)。治疗组中心力衰竭标示物心钠肽的表达量(7.28 ×106 +0.49×106绝对复制数/总RNAμg)明显低于对照组(32.67×106±2.78×106绝对复制数/总RNAμg)，(P＜0.0001)。治疗组炎性细胞因子IL-1β的表达量(0.298±0.04)明显低于对照组(0.818±0.252)，(P =0.0005)，而抗炎性细胞因子IL-1受体拮抗剂的表达量在治疗组0.112±0.009明显高于对照组(0.051±0.002)，(P＜0.0001)。结论卡维地洛对EAM有良好的治疗效果，其治疗机制可能是通过抑制炎性细胞因子同时增加抗炎性细胞因子等免疫调节作用而发挥。
목적통과검측심기조직중세포인자표체량적변화래평개잡유지락대대서실험성자신면역성심기염(EAM)적치료효과급기작용궤제。방법대서접충기구단백후피분위량조，치료조매일급여잡유지락，대조조급여부형제，치료효과재제21천진행평개。결과 실험조심기염증면적23.07％±1.6％여대조조33.65％±2.71％상비명현감소(P ＜0.0001)，좌실단축축단솔43.52％±3.53％여대조조32.3％±3.31％상비명현제고(P =0.0021)。치료조중심력쇠갈표시물심납태적표체량(7.28 ×106 +0.49×106절대복제수/총RNAμg)명현저우대조조(32.67×106±2.78×106절대복제수/총RNAμg)，(P＜0.0001)。치료조염성세포인자IL-1β적표체량(0.298±0.04)명현저우대조조(0.818±0.252)，(P =0.0005)，이항염성세포인자IL-1수체길항제적표체량재치료조0.112±0.009명현고우대조조(0.051±0.002)，(P＜0.0001)。결론잡유지락대EAM유량호적치료효과，기치료궤제가능시통과억제염성세포인자동시증가항염성세포인자등면역조절작용이발휘。
Objective We investigated whether the therapeutic effects of carvedilol are exerted in experimental autoimmune myocarditis(EAM). Methods After immunization, rats were orally administered either carvedilol or a vehicle control for 21 days. The heart weight to body weight ratio, the area of myocarditis,echocardiography parameters and the gene expression of atrial natriuretic peptide(ANP), IL-1β and IL-1 receptor antagonist(IL-1RA)were measured on day 21. Results Carvedilol was effective in controlling EAM,as apparent by a reduced area of myocarditis(23.07％ ± 1.6％ vs 33.65％ ± 2.71％ ; P ＜ 0. 0001), and reduced expression of the gene encoding ANP(7.28 × 106 t± 0. 49 × 106 vs 32.67 × 106 + 2.78 × 106 copy /total RNA μg;P＜0. 0001). Echocardiography revealed that carvedilol administration resulted in a significant improvement of total RNA μg;P ＜0. 0001). Echocardiography revealed that carvedilol administration resulted in a left ventricular fractional shortening(42.52％ ± 3.53％ vs 32.3％ ± 3.31％ ; P =0.002). The mRNA level of the IL-1β(0.298 ± 0.04 vs 0.818 ± 0. 252; P =0. 0005)was markedly decreased and the IL-1 RA (0.112 ± 0.009 vs 0.051 ± 0.002; P＜0.0001)was markedly increased in the carvedilol-treated group.Conclusions Carvedilol protects against acute EAM in rats. This cardioprotective effect may be attributed to the suppression of pro-inflammatory cytokines and promotion of anti-inflammatory cytokines.